With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions. [Ed. note: Investors should be extremely careful investing in nanocap stocks; do your own careful due diligence.]
The following 8 clinical-stage small cap companies, constituents in munKNEE’s latest index, our AI-focused Drug Discovery Stocks Index, use AI to facilitate the discovery and development of new drugs and trade on various Canadian and American stock exchanges. They are listed in order of their stock performances MTD in December along with their YTD performances, market capitalizations, and a description of each companies focus of operations.The munKNEE AI-focused Drug Discovery Stocks Index
- is focused on antibody design, creating new from scratch antibodies (“de novo antibodies”), and testing them in laboratories in a 6-week process.
- Market Capitalization: $254M
- has one of the world’s most extensive biological and chemical datasets and conducts millions of experiments per week using supercomputers, machine learning and automated robotic labs and has several compounds in phase 1 and 2 studies.
- Market Capitalization: $2.1B
- is developing an AI-driven allosteric drug-discovery platform to detect interactions that occur on a protein of interest with an initial focus on precision oncology and genetic diseases.
- Market Capitalization: $1.2B
- uses AI to focus on the search for, and analyzing of, the immune systems to find potential antibodies, then outsourcing their initial findings to their partners for further drug discovery.
- Market Capitalization: $1.6B
- offers specialized solutions for both small molecule discovery and biologics discovery focusing on structure prediction and protein engineering, including antibody modeling.
- Market Capitalization: $2.3B
- specializes in developing new classes of precision cancer drugs with novel mechanisms of action and “recycling” previously unsuccessful cancer drugs using machine learning algorithms, genomic data, and novel precision oncology biomarkers.
- Market Capitalization: $46M
- is collaborating with Bristol-Myers Squibb on a handful of drug candidates and has partnered with Sanofi, GSK and PathAI on drug discovery projects.
- Market Capitalization: $733M
- leverages existing approved drugs and/or clinically evaluated product candidates together with big data and machine learning algorithms to identify new therapeutic applications.
- Market Capitalization: $93M
SummaryThe munKNEE AI-focused Drug Discovery Stocks Index is up 26.2% MTD but remains down 3.7% YTD.More By This Author:
